Arbutus Biopharma Corporation - Common Stock (ABUS)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 2% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 53.8% with 72.8% net margin
- Revenue growing at 128% annually
Arbutus Biopharma Corporation - Common Stock (ABUS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $924 million . Key value metrics: P/E ratio 6.6, P/B ratio 3.55, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Arbutus Biopharma Corporation - Common Stock — Fundamental Analysis Summary
Arbutus Biopharma Corporation - Common Stock (ABUS) is currently trading 2% above its Graham Number of $4.58, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a low trailing P/E ratio of 6.6x.
On financial health, ABUS shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 53.8% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for ABUS is 94/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ABUS shows revenue growing at 128% year-over-year, with earnings growing at 52%.